Clinical and radiological determinants of prestroke cognitive decline in a stroke cohort

T Pohjasvaara, R Mäntylä, H J Aronen, M Leskelä, O Salonen, M Kaste, T Erkinjuntti

Abstract

Objectives—Stroke seems to be related to dementia more often than previously assumed and vascular factors are also related to Alzheimer's disease. The pathophysiology of poststroke dementia includes ischaemic changes in the brain, a combination of degenerative and vascular changes, and changes only related to Alzheimer’s disease. Some cognitive decline recognised after a stroke may be due to pre-existing cognitive decline. The aim of this study was to determine the clinical and radiological determinants of pre-stroke cognitive decline.

Methods—The study group comprised 337 of 486 consecutive patients aged 55 to 85 years who 3 months after ischaemic stroke completed a comprehensive neuropsychological test battery; structured medical, neurological, and mental status examination; interview of a knowledgeable informant containing structured questions on abnormality in the cognitive functions; assessment of social functions before the index stroke; and MRI.

Results—Frequency of pre-stroke cognitive decline including that of dementia was 9.2% (31/337). The patients with pre-stroke cognitive decline were older, more often had less than 6 years of education, and had history of previous stroke. Vascular risk factors did not differ significantly between these two groups. White matter changes (p=0.004), cortical entorhinal, hippocampal, and medial temporal atrophy (p<0.001), cortical frontal atrophy (p=0.008), and any central atrophy (p<0.01), but not the frequencies or volumes of old, silent, or all infarcts on MRI differentiated those with and without pre-stroke cognitive decline. The correlates of pre-stroke cognitive decline in logistic regression analysis were medial temporal cortical atrophy (odds ratio (OR) 7.5, 95% confidence interval (95%CI) 3.2–18.2), history of previous ischaemic stroke (OR 4.4, 95% CI 1.8–10.6), and education (OR 0.9, 95% CI 0.8–0.9).

Conclusions—History of previous stroke, but not volumes or frequencies was found to correlate with pre-stroke cognitive decline. Other associating factors were rather those usually associated with degenerative dementia: white matter changes and cerebral atrophy; and in multiple models medial temporal cortical atrophy and education. The possible overlap between two or more underlying diseases must be remembered in diagnosis and treatment of patients with vascular cognitive impairment.

Keywords: stroke; cognition; MRI

Cerebrovascular disease is associated with higher risk of dementia, and vascular factors are related to other causes of dementia.4 Stroke seems to be related to dementia more often than previously assumed and vascular factors are also related to Alzheimer's disease.6 These factors include white matter changes,7–10 cerebral amyloid angiopathy,11–13 and coexisting stroke.12 Stroke, risk factors for stroke, and Alzheimer's disease share common genetic factors, such as the ε4 allele of the apolipoprotein E gene.14–16 In conclusion, it has been found that vascular factors are more often related to dementia and cognitive impairment in Alzheimer's disease, than has previously been assumed.

The prevalence of dementia is increased after an ischaemic stroke.17–19 According to modified DSM-III criteria, Tatemichi et al found that 26.3% of stroke patients were demented 3 months after ischaemic stroke,20 34.6% were considered to have Alzheimer's disease with stroke, because functional and memory impairments preceded the index stroke.21 In the Helsinki Stroke Aging Memory Study cohort baseline findings, nearly 40% of patients found demented 3 months poststroke had cognitive decline before stroke.22 In conclusion, it has been found that the frequency of prestroke dementia in a series of stroke patients (mean age 75) was 16.3% (33/202) and in logistic regression analysis female sex, family dementia, leukoaraiosis, and cerebral atrophy were independently associated with prestroke dementia.

These findings emphasise that the pathophysiology of poststroke dementia includes ischaemic changes in the brain, a combination...
of degenerative and vascular changes, and changes only related to Alzheimer's disease. Therefore some cognitive decline recognised after a stroke may be due to pre-existing decline.

The aim of the present study was to determine the frequency of prestroke cognitive decline by standardised questionnaires of patients' relatives and to determine the radiological and clinical correlates of it.

**Subjects and methods**

Procedures of the Helsinki Stroke Aging Memory Study cohort have been detailed in a report on methods and baseline findings. Briefly, 486 consecutive patients aged 55 to 85 were evaluated 3 months after ischaemic stroke. Of these, 451 completed a clinical, neurological, and mental status examination. The excluded patients comprised one who refused, one with a reduced level of consciousness, one with severe hearing impairment, and 32 with severe aphasia. Of the 451 patients, 337 (74.7%) had brain MRI and a comprehensive neuropsychological examination. The 114 patients not included were 59 in whom MRI was not performed (contraindication in 27, refusal in 18, claustrophobia in two, severe illness in 11, obesity in one) and 55 who did not complete the cognitive test battery in detail (lack of sufficient cooperation in 23, refusal in 14, non-fluency in the Finnish language in five, severe aphasia in five, severe neglect in three, hearing or visual impairment in three, illiteracy in two). The 114 patients excluded were older (mean age, 73.5 ± 70.2 years; p < 0.001), less often had small vessel occlusion (1/114 = 27/337; p = 0.0064), and more often stroke of undetermined aetiology (82/114 versus 202/337; p = 0.0219), but they did not differ in terms of main demographic and clinical features including sex, education, and number, side, and site of stroke.

The subjects underwent a structured medical and neurological history based on review of all available hospital charts, interview of the subject and a knowledgeable informant, and a structured clinical and neurological examination performed by a board certified neurologist (TP). In addition, all the cases were reviewed by a senior neurologist (TE). The neurological examination focused on factors and features related to dementia and stroke similar to the method of the Memory Research Unit, Department of Neurology, University of Helsinki, and the National Stroke Data Bank. History of main vascular risk factors was obtained as described earlier.

Details of the clinical mental status examination, as well as assessment of emotional functions, are given in a previous report. The clinical cognitive assessment included the Folstein MMSE (maximum = 30). Aphasia was assessed clinically using the acute aphasia screening protocol. Assessment of emotional functions included the Beck depression scale completed by the patient (maximum = 60). The neuropsychological criteria for dementia were those of the American Psychiatric Association DSM-III. Cognitive domains of the DSM-III definition assessed by the neuropsychological test battery included memory functions (short and long term memory), executive functions, abstract thinking, judgment, aphasia, apraxia, agnosia, constructional and visuospatial abilities, and personality change. The detailed description of the assessment has been published.

Social functioning was assessed by the patient's ability to work, by the patient's ability to perform the instrumental activities of daily living (IADL) and activities of daily living (ADL) tests based on an interview with the patient and with a knowledgeable informant, and by neurologist's examination. Assessments that reflected functions before and 3 months after the index stroke were used. The scales used included the index of ADL (rating from 1 to 7), the IADL scale (maximum = 8), the functional activities questionnaire (maximum = 30), the Blessed functional activity scale (maximum = 17), and the Barthel index. In addition, the neurologist completed the clinical dementia rating (maximum = 3). Stroke related impairment was also assessed using the Rankin scale (maximum = 5) and the Scandinavian stroke scale (maximum = 58).

Assessment of prestroke cognitive decline was based on dementia criteria with the patient and a knowledgeable informant. The interviews included structured questions on abnormality in the cognitive domains as well as assessment of social functions before the index stroke. The beginning of the symptoms and their duration was asked for; the focus was especially in the period of 1 year before the index stroke. We used all available history from the patient and knowledgeable informant to get the most reliable answers to all the structured questions and based on the questionnaire, a board certified neurologist (TP) independently judged whether the patient had prestroke cognitive decline or not. All the cases were further reviewed by a senior neurologist (TE) and because we took only patients with clear cognitive impairment, there was no disagreement between the two neurologists. The patients also included those with borderline and definite dementia. However, we were unable to perform structured diagnosis of prestroke dementia; the focus was on prestroke cognitive decline. Our definition accords with that of Tatemichi et al.

Education was divided into two categories: low (0 to 6 years of formal education) and high (>6 years of formal education).

**Magnetic Resonance Imaging**

Brain MRI was performed 3 months after index stroke with a superconducting MRI system operating at 1.0 T (Siemens Magnetom, Erlangen, Germany). Transaxial T2, PD, and T1 weighted images were obtained with the SE technique. The repetition time (TR) for T2 and PD weighted images was 3000 ms, echo time (TE) 15–90 ms, and number of excitations (NEX) 1. The corresponding parameters for T1 weighted images were TR/TE/NEX 400/15/2. The slice thickness was 5 mm, gap 0, field of view 230 mm, matrix size 256 × 256.
pixels, and number of slices 26 on every pulse sequence. In addition a three dimensional gradient echo TR/TE/alpha/NEX 30/5/40/1 -sequence with 64 3 mm thick coronal sections was used.

### BRAIN INFARCTS

All MR images were reviewed by the same neuroradiologist (RM) blinded to the clinical data. The number, location, and size of focal lesions were recorded. Lesions equivalent to the signal characteristics of CSF on T1 weighted images and measuring over 3 mm in diameter, as well as wedge shaped corticobulbar lesions were regarded as brain infarcts. The size of the lesions was allocated to four groups: diameter 3–9 mm, 10–29 mm, 30–59 mm, and ≥60 mm, and the radii used for calculations were 3, 10, 20, and 30 mm respectively. The volume of the lesion was estimated using the formula for calculating the volume of a sphere.

The history of previous and present (index stroke) including clinical symptoms and radiological lesions on MRI were reviewed together with the board certified neurologist (TP) and neuroradiologist (RM). The infarcts not related to the present symptoms, but which were related to episodes documented in the patient’s history, were defined as old infarcts. The infarcts not having any relation to the patient’s present or previous symptoms were defined as silent infarcts.

### WHITE MATTER CHANGES

For white matter hyperintensity (WMHI) rating nine slices (L1, L2, L3, H1, H2, H3, S1, S2, S3) were chosen to represent the different parts of white matter. Slice L1 was the lowest slice where the frontal horns of lateral ventricles could be seen and S1 the first slice above the roof of the lateral ventricles.

White matter hyperintensities were rated in four white matter areas: periventricular, deep, watershed, and subcortical white matter. Periventricular hyperintensities (PVHIs) were in contact with the ventricular wall; deep WMHIs (DWMHIs) were separated from the ventricular system by a strip of normal looking white matter and were located outside the watershed. The subcortical region was considered to represent the area <5 mm beneath the cortex. White matter hyperintensities which affected some part of this area and were located outside watershed were rated as subcortical HIs. Watershed HIs and PVHIs were analysed on six slices (L1, L2, L3, H1, H2, H3); DWMHIs on three slices (S1, S2, S3); and subcortical HIs on nine slices (L1, L2, L3, H1, H2, H3, S1, S2, S3).

Periventricular hyperintensities (PVHIs) around the frontal and posterior horns were classified based on size and shape into small cap, large cap, and extending cap (small cap ≤5 mm in diameter, rounded with regular margins; large cap 6 to 10 mm in diameter, mostly with regular margins; extending cap >10 mm in diameter, irregular margins). Periventricular hyperintensities along the bodies of lateral ventricles were classified based on thickness and shape into thin lining, smooth halo and irregular halo (thin lining ≤5 mm, regular margins; smooth halo 6 to 10 mm, smooth and mostly regular margins; irregular halo >10 mm, irregular margins and extending into the deep white matter).

White matter hyperintensities in the subcortical, deep, and watershed areas were classified based on size (greatest diameter) and shape into small focal, large focal, focal confluent, diffusely confluent, and extensive white matter change (small focal, punctate hyperintensities ≤5 mm, mostly rounded; large focal 6 to 10 mm, mostly rounded; focal confluent 11 to 25 mm, often various shapes and may have irregular borders; diffusely confluent >25 mm, mostly irregular borders; and extensive white matter change, diffuse hyperintensity without distinct focal lesions affecting most of the white matter area). The number of each type of hyperintensity was counted, and extensive white matter change was rated as absent or present.

The extent of PVHIs and WMHIs on PD weighted images was then graded in the following way using a four point scale proposed by Fazekas et al.\(^4\) PVHI grade 0=absence of PVHIs, 1=small or large caps or thin lining, 2=smooth halo, 3=extending caps or irregular halo; WMHI grade 0=absence of WMHIs, 1=small or large focal lesions only, 2=at least one focal confluent lesion, no diffusely confluent lesions nor extensive white matter change, 3=at least one diffusely confluent lesion or extensive white matter change.

### BRAIN ATROPHY

Brain atrophy was rated from 0 to 3 corresponding to atrophy ratings “no, mild, moderate, and severe”. Ratings were made by comparison to standard images in the following way: grade 0=none=equal to standard image 0 or less than in standard image 1; grade 1=mild=equal to standard 1 or less than standard 2; grade 2=moderate=equal to standard 2 or less than standard 3; and grade 3=severe=equal to standard 3 or more than in standard images. Cortical and central brain atrophy were rated separately; cortical atrophy in the frontal, parietal, and occipital lobes, in the temporal neocortex, entorhinal cortex (parahippocampal gyrus), and hippocampal formation as well as in the cerebellum and vermis, and central atrophy in the temporal, frontal, and occipital horns of the lateral ventricles as well as the bodies, in the third and fourth ventricles. If possible, both sides were rated separately. The atrophy ratings were based on T1 weighted images and the temporal structures were evaluated on three coronal slices, (the slice showing the interpeduncular cistern and ±1 slice). In the analysis of cortical atrophy, attention was paid to the width of sulci and the thickness of gyri. In addition to general cortical atrophy, focal cortical atrophy in the frontal, parietal, occipital or temporal lobes, as well as the cerebellum was registered.
Determinants of prestroke cognitive decline in a stroke cohort

Table 1 Characteristics of patients without and with cognitive decline prestroke in the Helsinki Stroke Aging Memory Study (SAM) Cohort (n=337)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>No cognitive decline prestroke (n=306)</th>
<th>Cognitive decline prestroke (n=31)</th>
<th>All (n=337)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (SD)</td>
<td>69.9 (7.4)</td>
<td>72.9 (9.9)</td>
<td>70.2 (7.7)</td>
<td>0.0363</td>
</tr>
<tr>
<td>Female sex (%)</td>
<td>149 (48.7)</td>
<td>19 (61.3)</td>
<td>168 (49.9)</td>
<td>0.1813</td>
</tr>
<tr>
<td>Low education (%)</td>
<td>78 (26.2)</td>
<td>14 (45.2)</td>
<td>92 (28.0)</td>
<td>0.0250</td>
</tr>
<tr>
<td>Risk factor for stroke:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td>73 (23.9)</td>
<td>6 (19.4)</td>
<td>79 (23.4)</td>
<td>0.5729</td>
</tr>
<tr>
<td>Cardiac failure</td>
<td>59 (19.3)</td>
<td>10 (32.3)</td>
<td>69 (20.5)</td>
<td>0.0899</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>48 (15.7)</td>
<td>8 (25.8)</td>
<td>56 (16.6)</td>
<td>0.1492</td>
</tr>
<tr>
<td>History of myocardial infarction</td>
<td>59 (19.3)</td>
<td>3 (9.7)</td>
<td>62 (18.4)</td>
<td>0.1885</td>
</tr>
<tr>
<td>High total cholesterol</td>
<td>56 (18.3)</td>
<td>3 (9.7)</td>
<td>59 (17.5)</td>
<td>0.2286</td>
</tr>
<tr>
<td>Smoking, history or current</td>
<td>157 (51.3)</td>
<td>13 (41.9)</td>
<td>170 (50.5)</td>
<td>0.3200</td>
</tr>
<tr>
<td>Alcohol use (at least once a week)</td>
<td>81 (26.6)</td>
<td>9 (29.6)</td>
<td>90 (26.8)</td>
<td>0.7669</td>
</tr>
<tr>
<td>None of the above</td>
<td>17 (5.6)</td>
<td>0 (0.0)</td>
<td>17 (5.1)</td>
<td>0.1766</td>
</tr>
<tr>
<td>History of previous CVD:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transient ischaemic attack</td>
<td>42 (13.7)</td>
<td>2 (6.5)</td>
<td>44 (13.1)</td>
<td>0.2520</td>
</tr>
<tr>
<td>Ischaemic stroke</td>
<td>55 (18.0)</td>
<td>15 (48.4)</td>
<td>70 (20.8)</td>
<td>0.0000</td>
</tr>
<tr>
<td>Subarachnoidal haemorrhage</td>
<td>4 (1.3)</td>
<td>1 (3.2)</td>
<td>5 (1.5)</td>
<td>0.3998</td>
</tr>
<tr>
<td>Intracerebral haemorrhage</td>
<td>3 (1.0)</td>
<td>0 (0.0)</td>
<td>3 (0.9)</td>
<td>0.5797</td>
</tr>
</tbody>
</table>

Table 2 Percentages of moderate and severe degree of white matter changes and cerebral atrophy in patients with and without prestroke cognitive decline in the Helsinki Stroke Aging Memory (SAM) Study Cohort (n=337)

<table>
<thead>
<tr>
<th>White matter changes:</th>
<th>No cognitive decline prestroke (n=306)</th>
<th>Cognitive decline prestroke (n=31)</th>
<th>All (n=337)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parietal</td>
<td>20.8</td>
<td>44.8</td>
<td>22.9</td>
<td>0.0032</td>
</tr>
<tr>
<td>Occipital</td>
<td>41.2</td>
<td>48.3</td>
<td>41.9</td>
<td>0.4620</td>
</tr>
<tr>
<td>Entorhinal</td>
<td>21.0</td>
<td>69.0</td>
<td>25.2</td>
<td>0.0000</td>
</tr>
<tr>
<td>Hippocampal</td>
<td>15.5</td>
<td>55.2</td>
<td>19.1</td>
<td>0.0000</td>
</tr>
<tr>
<td>Medial temporal</td>
<td>22.0</td>
<td>69.0</td>
<td>26.2</td>
<td>0.0089</td>
</tr>
<tr>
<td>Mean Fazekas white matter score (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Frontal</td>
<td>3.1 (1.5)</td>
<td>4.0 (1.7)</td>
<td>3.2 (1.5)</td>
<td>0.0037</td>
</tr>
<tr>
<td>Parietal</td>
<td>41.2</td>
<td>58.6</td>
<td>42.3</td>
<td>0.0070</td>
</tr>
<tr>
<td>Occipital</td>
<td>41.2</td>
<td>48.3</td>
<td>41.9</td>
<td>0.4620</td>
</tr>
<tr>
<td>Entorhinal</td>
<td>21.0</td>
<td>69.0</td>
<td>25.2</td>
<td>0.0000</td>
</tr>
<tr>
<td>Hippocampal</td>
<td>15.5</td>
<td>55.2</td>
<td>19.1</td>
<td>0.0000</td>
</tr>
<tr>
<td>Medial temporal</td>
<td>22.0</td>
<td>69.0</td>
<td>26.2</td>
<td>0.0089</td>
</tr>
</tbody>
</table>

Results

The statistics were analysed using the BMDP and SAS programs.24 45

The degree of moderate and severe white matter changes and cerebral atrophy is presented in table 2. Mean Fazekas white matter score of those with prestroke cognitive decline was significantly higher compared with those without prestroke cognitive decline (4.0 (1.7) v 3.1 (1.5); p=0.0037). Moderate and severe cortical frontal (62.1% v 36.8%; p=0.0078), entorhinal (69.0% v 21.0%; p<0.0001), hippocampal (55.2% v 15.5%; p<0.0001), and medial temporal atrophy (69.0% v 22.0%; p<0.0001) were significantly more common among those with than those patients without prestroke cognitive decline. Moderate and...
Table 3  Frequency (SD) and mean volumes (cm	extsuperscript{3}, SD) of infarcts on MRI in patients without and with cognitive decline prestroke in the Helsinki Stroke Aging Memory Study (SAM) Cohort (n=337)

<table>
<thead>
<tr>
<th>Variable</th>
<th>No cognitive decline prestroke (n=306)</th>
<th>Cognitive decline prestroke (n=31)</th>
<th>Silent infarcts</th>
<th>Cognitive decline prestroke (n=306)</th>
<th>Cognitive decline prestroke (n=31)</th>
<th>All (n=337)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frequency of infarcts:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right side</td>
<td>0.2 (0.9)</td>
<td>0.5 (1.0)</td>
<td>0.8 (1.2)</td>
<td>0.8 (1.0)</td>
<td>1.5 (0.1)</td>
<td>1.5 (0.3)</td>
<td>p=0.074</td>
</tr>
<tr>
<td>Left side</td>
<td>0.3 (1.0)</td>
<td>0.2 (0.6)</td>
<td>0.7 (1.0)</td>
<td>0.7 (0.9)</td>
<td>1.4 (1.4)</td>
<td>1.3 (1.9)</td>
<td>p=0.069</td>
</tr>
<tr>
<td>All</td>
<td>0.6 (1.4)</td>
<td>0.8 (1.1)</td>
<td>1.5 (1.8)</td>
<td>1.5 (1.5)</td>
<td>3.0 (2.4)</td>
<td>3.2 (2.0)</td>
<td>p=0.228</td>
</tr>
<tr>
<td>Volume of infarcts:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right side</td>
<td>20.4 (33.5)</td>
<td>17.8 (37.7)</td>
<td>2.8 (6.7)</td>
<td>4.9 (8.4)</td>
<td>22.8 (38.5)</td>
<td>32.6 (51.3)</td>
<td>p=0.005</td>
</tr>
<tr>
<td>Left side</td>
<td>10.6 (21.8)</td>
<td>2.6 (2.3)</td>
<td>3.5 (9.4)</td>
<td>0.8 (1.5)</td>
<td>11.4 (21.3)</td>
<td>10.6 (26.4)</td>
<td>p=0.771</td>
</tr>
<tr>
<td>All</td>
<td>17.2 (29.8)</td>
<td>14.4 (32.7)</td>
<td>4.5 (10.2)</td>
<td>4.0 (7.3)</td>
<td>26.5 (39.4)</td>
<td>36.7 (50.7)</td>
<td>p=0.204</td>
</tr>
</tbody>
</table>

The mean frequencies and volumes (cm	extsuperscript{3}) of old, silent, and all infarcts are presented in table 3. The mean frequencies and volumes of old, silent and all infarcts, right and left sided and all analysed separately, did not significantly differentiate the patients with cognitive decline from those without it.

The variables that significantly differentiated the patients with and without prestroke cognitive decline were put into a multiple logistic model (table 4). Prestroke cognitive decline was related to medial temporal cortical atrophy (odds ratio (OR) 7.5, 95% confidence interval (95%CI) 3.2–18.2), to history of previous ischaemic stroke (OR 4.4, 95% CI 1.8–10.6) and to education (OR 0.9, 95% CI 0.8–0.9).

Three month outcome was worse in patients with prestroke cognitive decline compared with those without measured by all ADL scales and cognitive scales (table 5). The amount of patients found demented 3 months after stroke was significantly higher in those patients with prestroke cognitive decline compared with those without (20 (64.5%) vs 87 (28.4%); p<0.0001).

Discussion

We report here the largest well defined stroke cohort thus far to examine the correlates related to prestroke cognitive decline. Based on interviews with the patient and a knowledgeable informant, prestroke cognitive decline including patients with dementia, was found in 9.2% of the patients (mean age 70.2) with ischaemic stroke. In an earlier study\textsuperscript{21} prestroke dementia was found in 16.3% of the patients with stroke (mean age 75) by structured questionnaires of the relatives. In meta-analysis of nine European studies\textsuperscript{40} age specific prevalence (%) of pre-existing dementia in the groups aged 40 to 69, 70 to 79 and > 80 years was 4.4%, 9.7%, and 33.3%, respectively in stroke patients. The corresponding prevalence in patients with dementia (whatever the aetiology) in community based studies were 0.5%, 5.0%, and 19.1%.\textsuperscript{41} Thus in the present study we think that we have avoided overestimation of this prevalence. We were able to investigate in detail (including brain MRI) 75% of the clinically testable patients. The non-participants were older and more often had stroke of underdetermined aetiology. This factor might have caused a slight underestimation of the frequency of prestroke cognitive impairment. Altogether 11.8% of all the clinically testable patients had prestroke cognitive impairment and in the present approach a little less, 9.2% of the patients had prestroke cognitive impairment and also MRI. However, this selection bias is comparable with that in other similar cohorts.\textsuperscript{12 38}

Previous stroke, but not transient ischaemic attack or any known risk factor for stroke, old, silent, or all infarcts on MRI, was associated with prestroke cognitive decline. Cerebral atrophy and white matter changes were strongly associated with prestroke cognitive decline. In the logistic model the independent correlates of prestroke cognitive decline were medial temporal cortical atrophy, history of previous stroke, and education. In an earlier study\textsuperscript{21} severe central temporal (65.5% vs. 28.0%; p=0.0001), frontal (65.5% vs. 35.1%; p=0.0013), lateral (65.5% vs. 38.9%; p=0.0054), and occipital (75.9% vs. 41.9%; p=0.0004) atrophy were significantly more common among the patients with prestroke cognitive decline than the patients without it (table 2).
Determinants of pre-stroke cognitive decline in a stroke cohort

Factors independently associated with pre-existing dementia were those usually associated with degenerative dementia rather than those associated with vascular dementia: cerebral atrophy, leukoaraiosis, family history of dementia, and female sex. In that study previous stroke, transient ischaemic attack, silent infarcts, or the presence of old infarcts on CT were not associated with pre-existing dementia.

Assessment of pre-stroke cognitive decline was based on interviews with the patient and a knowledgeable informant. The interviews included structured questions on abnormality in the cognitive domains as well as assessment of social functions before the index stroke. This kind of evaluation has certain limits, because it is based on a retrospective questionnaire, but has been used in earlier studies in structured interviews used for epidemiological studies for patients still alive or even after a patient’s death, and also in stroke patients. The information from the relatives in the diagnosis of dementia has proved useful also when recorded in the unstructured manner of the clinical history. Being aware of the limitations of our evaluation, we are satisfied with the definition of pre-stroke cognitive decline instead of dementia.

Current epidemiological, clinical, and neuropathological evidence points to a substantial overlap between Alzheimer’s disease and vascular dementia and suggests that vascular pathology, the traditional cornerstone of the differential diagnosis between the two entities, may not represent as clear a line of demarcation between the two entities, pathology, the traditional cornerstone of the diagnostic criteria for dementia in general and vascular dementia. This needs to be established in the areas of diagnostic criteria for dementia in general and vascular dementia and cognitive decline in particular. Some cognitive decline recognised after a stroke seems to be due to pre-existing decline. The possible overlap between two or more underlying diseases must be remembered when and the use of conventional stroke preventives may be useful. Pentoxifylline, a haemorheological agent, and propentofylline, an adenosine uptake/phosphodiesterase inhibitor with neuroprotective properties, have shown promise in protecting the brain from ischaemia. Donepezil, approved for use in Alzheimer’s disease, could be effective in vascular dementia, especially if there is mixed vascular dementia and Alzheimer’s disease.

The prevalence of both stroke and Alzheimer’s disease increase with age, and vascular disease may be an important predictor of the presence and severity of cognitive impairment in older people. Kuller et al demonstrated that vascular changes on MRI, measures of brain atrophy, ApoE-4, and age, education, and race are associated with low cognitive scores among older people. An important precursor to preventive and treatment strategies for vascular dementia is diagnostic consensus. This needs to be established in the areas of diagnostic criteria for dementia in general and vascular dementia and cognitive decline in particular. Some cognitive decline recognised after a stroke seems to be due to pre-existing decline. The possible overlap between two or more underlying diseases must be remembered in diagnosis, treatment, and development of new treatments to patients with vascular cognitive impairment.

This study was supported in part by grants from the Medical Council of the Academy of Finland (ROA, HJA, TE); the Clinical Research Institute, Helsinki University Central Hospital (TP); the Finnish Alzheimer Foundation for Research, Helsinki (TP, TE); the Paavo Nurmi Foundation, Helsinki, Finland

Factors independently associated with pre-existing dementia were those usually associated with degenerative dementia rather than those associated with vascular dementia: cerebral atrophy, leukoaraiosis, family history of dementia, and female sex. In that study previous stroke, transient ischaemic attack, silent infarcts, or the presence of old infarcts on CT were not associated with pre-existing dementia.

Assessment of pre-stroke cognitive decline was based on interviews with the patient and a knowledgeable informant. The interviews included structured questions on abnormality in the cognitive domains as well as assessment of social functions before the index stroke. This kind of evaluation has certain limits, because it is based on a retrospective questionnaire, but has been used in earlier studies in structured interviews used for epidemiological studies for patients still alive or even after a patient’s death, and also in stroke patients. The information from the relatives in the diagnosis of dementia has proved useful also when recorded in the unstructured manner of the clinical history. Being aware of the limitations of our evaluation, we are satisfied with the definition of pre-stroke cognitive decline instead of dementia.

Current epidemiological, clinical, and neuropathological evidence points to a substantial overlap between Alzheimer’s disease and vascular dementia and suggests that vascular pathology, the traditional cornerstone of the differential diagnosis between the two entities, may not represent as clear a line of demarcation between the two entities, pathology, the traditional cornerstone of the diagnostic criteria for dementia in general and vascular dementia. This needs to be established in the areas of diagnostic criteria for dementia in general and vascular dementia and cognitive decline in particular. Some cognitive decline recognised after a stroke seems to be due to pre-existing decline. The possible overlap between two or more underlying diseases must be remembered when and the use of conventional stroke preventives may be useful. Pentoxifylline, a haemorheological agent, and propentofylline, an adenosine uptake/phosphodiesterase inhibitor with neuroprotective properties, have shown promise in protecting the brain from ischaemia. Donepezil, approved for use in Alzheimer’s disease, could be effective in vascular dementia, especially if there is mixed vascular dementia and Alzheimer’s disease.

The prevalence of both stroke and Alzheimer’s disease increase with age, and vascular disease may be an important predictor of the presence and severity of cognitive impairment in older people. Kuller et al demonstrated that vascular changes on MRI, measures of brain atrophy, ApoE-4, and age, education, and race are associated with low cognitive scores among older people. An important precursor to preventive and treatment strategies for vascular dementia is diagnostic consensus. This needs to be established in the areas of diagnostic criteria for dementia in general and vascular dementia and cognitive decline in particular. Some cognitive decline recognised after a stroke seems to be due to pre-existing decline. The possible overlap between two or more underlying diseases must be remembered in diagnosis, treatment, and development of new treatments to patients with vascular cognitive impairment.

This study was supported in part by grants from the Medical Council of the Academy of Finland (ROA, HJA, TE); the Clinical Research Institute, Helsinki University Central Hospital (TP); the Finnish Alzheimer Foundation for Research, Helsinki (TP, TE); the Paavo Nurmi Foundation, Helsinki, Finland.
Helsinki University Central Hospital (HJA); Finnish Cultural Foundation (MLC); and the Oscar Offiänd Stiftelse (ML). We thank Vesa Kuusela, senior research officer, Statistics Finland, Helsinki, for statistical support and review.


Clinical and radiological determinants of prestroke cognitive decline in a stroke cohort

T Pohjasvaara, R Mäntylä, H J Aronen, M Leskelä, O Salonen, M Kaste and T Erkinjuntti

J Neurol Neurosurg Psychiatry 1999 67: 742-748
doi: 10.1136/jnnp.67.6.742

Updated information and services can be found at:
http://jnnp.bmj.com/content/67/6/742

These include:

References
This article cites 46 articles, 25 of which you can access for free at:
http://jnnp.bmj.com/content/67/6/742#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Stroke (1449)
Memory disorders (psychiatry) (1390)
Dementia (1020)
Drugs: CNS (not psychiatric) (1945)
Psychiatry of old age (338)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/